VPH: Announces higher revenue guidance for Q4/2022. VALEO PHARMA RAISES Q4 AND FULL YEAR 2022 REVENUE GUIDANCE
Valeo Pharma Inc. has raised revenue guidance for its fourth quarter of 2022 to $12.5-million to $13-million, an increase of 14 per cent to 18 per cent over previously issued guidance of $11-million. The company is also increasing its fiscal 2022 revenue guidance to $27.5-million to $28-million, a forecasted increase exceeding 100 per cent compared with fiscal 2021 revenues of $13.6-million.
VPH is trading at only 67 cents per share.
Fidelity bought 1,860,000 shares since July 4/2022.